SCM
TRML

Superstring Capital Management’s Tourmaline Bio TRML Stock Holding History

Superstring Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,104
Closed -$748K – 47
2024
Q3 		$748K Sell
29,104
-66,125
-69% -$1.1M 0.65% 21
2024
Q2 		$1.22M Buy
95,229
+25,257
+36% +$406K 1.54% 19
2024
Q1 		$1.6M Buy
+69,972
New +$2.47M 1.06% 25

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Superstring Capital Management's TRML Position: Q4 2024 in Review

Superstring Capital Management sold out of Tourmaline Bio (TRML) in Q4 2024, closing a stake of 29,104 shares — an estimated $748K sold.

Superstring Capital Management first reported a position in TRML in Q1 2024 and held it in 3 quarters. The position peaked at $1.6M in Q1 2024. 101 funds tracked by Wall St. Rank hold TRML as of Q4 2024.

  • Superstring Capital Management reported no remaining Tourmaline Bio position as of Q4 2024 after selling out during the quarter.
  • Superstring Capital Management sold 29,104 Tourmaline Bio shares in Q4 2024, an estimated $748K.
  • Superstring Capital Management first reported a position in Tourmaline Bio in Q1 2024 and held it in 3 quarters.
  • Superstring Capital Management's Tourmaline Bio position peaked at $1.6M in Q1 2024.
  • 101 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2024.

Based on Superstring Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.